Your browser doesn't support javascript.
loading
Infralow-frequency transcranial magnetic stimulation as a therapy for generalized anxiety disorder: A randomized clinical trial.
Zeng, Shufei; Tang, Chong; Su, Meilei; Luo, Xian; Liang, Hanwen; Yang, Lulu; Zhang, Bin.
Afiliação
  • Zeng S; Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
  • Tang C; Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
  • Su M; Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
  • Luo X; Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
  • Liang H; Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
  • Yang L; Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China; Guangdong Mental Health Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510515, Guangdong Province, China.
  • Zhang B; Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China. Electronic address: zhang73bin@hotmail.com.
Compr Psychiatry ; 117: 152332, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35763873
ABSTRACT

BACKGROUND:

Generalized anxiety disorder (GAD) is a common chronic mental disorder, and it also can cause depressive symptoms and cognitive impairment. The primary aim of this study was to determine whether inflow-frequency transcranial magnetic stimulation (ILF-TMS) improves anxiety symptoms in patients with GAD.

METHODS:

Sixty-two patients with GAD were randomly divided into 2 groups. Thirty-one patients in the active ILF-TMS group and 31 patients in the sham ILF-TMS group. All participants were assessed at baseline, week 2, week 4 and week 12. The intention-to-treat methodology was used for the analysis.

RESULTS:

The response rate was higher in the active group than in the sham group, with a significant difference at week 12 (response rate 80.6% vs. 54.8%, respectively; P = 0.03). Although the remission rate was higher in the active group at week 12, there was no statistically significant difference between the groups (remission rate 71.0% vs. 48.4%; P > 0.05). No statistically significant differences on the Hamilton Depression Rating Scale, Clinical Global Impression scale, and neurocognitive test between groups were observed (overall P > 0.05). Adverse events that occurred in the active group were similar to those in the sham group, with no significant differences (P > 0.05).

CONCLUSION:

The response rate was higher in the active group at the end of the trial, which indicated that ILF-TMS may be an effective and safe adjunctive tool to improve anxiety symptoms in patients with GAD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article